MMM 3M CO
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 66740 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.7%
TTM net income YoY4.0%
TTM EPS YoY7.0%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin39.5%
Operating margin18.8%
Net margin14.0%
FCF margin10.6%
EBITDA margin24.4%
Returns
ROE80.8%
ROA9.2%
ROIC (approx.)28.5%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets87.0%
Debt / equity3.63x
Current ratio1.41x
Interest coverage5.54x
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio-0.2%
Payout ratio45.3%
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.58B | $6.50B | $6.03B | $6.13B | $6.52B | $6.34B | $5.95B | $6.01B |
| Cost of revenue | $3.80B | $3.82B | $3.57B | $4.08B | $3.79B | $3.65B | $3.48B | $3.74B |
| Gross profit | $2.78B | $2.68B | $2.46B | $2.06B | $2.73B | $2.70B | $2.48B | $2.27B |
| SG&A expense | $921.00M | $1.06B | $744.00M | $965.00M | $820.00M | $1.27B | $945.00M | $899.00M |
| Operating income | $1.56B | $984.00M | $1.40B | $796.00M | $1.45B | $1.14B | $1.25B | $1.08B |
| Interest expense | $217.00M | $202.00M | $214.00M | $222.00M | $232.00M | $237.00M | $255.00M | $252.00M |
| Pretax income | $1.67B | $1.12B | $878.00M | $758.00M | $1.15B | $923.00M | $1.39B | $759.00M |
| Income tax | $261.00M | $183.00M | $221.00M | $185.00M | $308.00M | $245.00M | $265.00M | $33.00M |
| Net income | $1.37B | $933.00M | $653.00M | $577.00M | $834.00M | $723.00M | $1.12B | $728.00M |
| EBITDA | $1.89B | $1.32B | $1.72B | $1.23B | $1.75B | $1.43B | $1.54B | $1.41B |
| EPS (basic) | 2.65 | 1.79 | 1.23 | — | 1.56 | 1.35 | 2.05 | 1.34 |
| EPS (diluted) | 2.63 | 1.78 | 1.23 | — | 1.55 | 1.34 | 2.04 | 1.33 |
| Dividends declared per share | 0.78 | 0.78 | 0.78 | 0.73 | 0.73 | 0.73 | 0.73 | 0.70 |
| Weighted avg. shares (diluted) | 522.60M | 522.40M | 532.80M | — | 538.10M | 540.60M | 547.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.83B | $2.96B | $3.73B | $5.24B | $4.67B | $3.71B | $6.33B | $5.60B |
| Receivables | $4.12B | $3.93B | $3.75B | $3.53B | $3.78B | $3.76B | $3.50B | $3.19B |
| Inventory | $4.08B | $3.77B | $3.69B | $3.66B | $3.89B | $4.08B | $3.87B | $3.70B |
| Current assets | $16.71B | $14.11B | $14.39B | $16.39B | $16.09B | $13.43B | $15.66B | $15.88B |
| PP&E, net | $6.97B | $6.88B | $6.96B | $7.10B | $7.25B | $7.39B | $7.36B | $7.39B |
| Goodwill | $7.34B | $6.37B | $6.38B | $6.42B | $6.42B | $6.43B | $6.34B | $6.28B |
| Intangibles | $2.05B | $1.05B | $1.08B | $1.10B | $1.13B | $1.16B | $1.19B | $1.21B |
| Total assets | $39.53B | $34.92B | $35.44B | $37.73B | $37.61B | $37.99B | $39.95B | $39.87B |
| Current liabilities | $11.87B | $11.38B | $9.03B | $9.60B | $8.73B | $7.81B | $9.45B | $11.26B |
| Short-term debt | $2.44B | $1.65B | $1.65B | $1.67B | $749.00M | $669.00M | $1.17B | $1.92B |
| Long-term debt | $12.56B | $10.90B | $10.91B | $10.93B | $11.85B | $12.48B | $12.31B | $11.12B |
| Total debt | $15.00B | $12.55B | $12.56B | $12.60B | $12.60B | $13.15B | $13.48B | $13.04B |
| Total liabilities | $34.39B | $31.92B | $32.12B | $32.99B | $32.94B | $33.64B | $35.43B | $35.97B |
| Shareholders' equity | $4.13B | $2.95B | $3.26B | $4.70B | $4.63B | $4.29B | $4.46B | $3.84B |
| Net debt | $10.16B | $9.60B | $8.83B | $7.37B | $7.93B | $9.43B | $7.15B | $7.44B |
| Shares outstanding | 516.73M | 515.72M | 521.57M | 530.28M | 531.23M | 532.63M | 538.18M | 539.47M |
| Cash flow statement | ||||||||
| Operating cash flow | $486.00M | $986.00M | $574.00M | $1.58B | $1.76B | -$954.00M | -$79.00M | $1.82B |
| Capital expenditure | $256.00M | $223.00M | $225.00M | $248.00M | $218.00M | $208.00M | $236.00M | $291.00M |
| Free cash flow | $230.00M | $763.00M | $349.00M | $1.33B | $1.54B | -$1.16B | -$315.00M | $1.53B |
| Investing cash flow | -$2.09B | -$483.00M | $60.00M | -$405.00M | $465.00M | $70.00M | $1.22B | -$1.15B |
| Financing cash flow | $3.48B | -$1.33B | -$2.12B | -$617.00M | -$1.21B | -$1.77B | -$422.00M | -$1.08B |
| Depreciation & amortization | $336.00M | $335.00M | $326.00M | $430.00M | $298.00M | $290.00M | $290.00M | $322.00M |
| Stock-based compensation | $46.00M | $41.00M | $80.00M | $43.00M | $53.00M | $44.00M | $85.00M | $47.00M |
| Dividends paid | $403.00M | $401.00M | $412.00M | $387.00M | $389.00M | $390.00M | $396.00M | $378.00M |
| Share buybacks | $232.00M | $994.00M | $2.00B | $552.00M | $472.00M | $953.00M | $1.27B | $705.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.